Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com -- Thermo Fisher Scientific Inc (BVMF:TMOS34). (NYSE: NYSE:TMO), a global leader in science service, announced today that it has reached a definitive agreement to purchase the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.1 billion in cash.
The Purification & Filtration business of Solventum is a leading provider of technologies used in the production of biologics, as well as in medical technologies and industrial applications. The business operates worldwide, with locations throughout the Americas, Europe, Middle East, Africa, and the Asia-Pacific region. It employs about 2,500 people. In 2024, the business generated around $1 billion in revenue.
The acquisition of Solventum’s business fits well with Thermo Fisher’s bioproduction business. Thermo Fisher currently has a leading portfolio in cell culture media and single-use technologies. The innovative filtration portfolio of Solventum expands Thermo Fisher’s capabilities in the development and manufacturing of biologics, covering both upstream and downstream workflows.
Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher, stated that the addition of Solventum’s business aligns strategically with the company and will create considerable value for customers and shareholders. He emphasized that Solventum’s solutions would be appreciated by their customers and would further demonstrate Thermo Fisher’s disciplined capital deployment strategy, which has a proven history of generating shareholder value.
Casper further noted that as a trusted partner to their customers, Solventum’s Purification & Filtration business would enhance and add unique capabilities to their bioprocessing portfolio. This would better serve their customers in the rapidly expanding market. He expressed eagerness to welcome the new colleagues to Thermo Fisher.
The deal is expected to be finalized by the end of 2025, subject to standard closing conditions and regulatory approvals. After the transaction concludes, Solventum’s Purification & Filtration business will become a part of Thermo Fisher’s Life Sciences Solutions segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.